SecBot SecBot
SECBOTREPLAY Home › Report › DRTSW

DRTSW · Alpha Tau completed enrollment of 88 patients in its U.S

Alpha Tau Medical Ltd. · 6-K filed May 8, 2026 at 09:00 ET

At the news

BULLISHIMPACT 6/10

6-K filed May 8, 2026 at 09:00 ET

Alpha Tau completed enrollment of 88 patients in its U.S. pivotal ReSTART trial for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, a key milestone toward potential FDA PMA approval. The company has Breakthrough Device Designation and initiated the modular PMA process in January 2026. No financial data was provided; the event is a clinical milestone with no revenue impact yet.

  • Enrolled all 88 patients in the ReSTART pivotal trial for recurrent cSCC
  • First U.S. pivotal study to complete enrollment for Alpha Tau
  • Alpha DaRT received Breakthrough Device Designation from FDA
  • First module of modular PMA application submitted in January 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access